BioMarin Pharmaceutical stock is trading -42.31% below its average target price of $97.15 after dropping -5.0% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $65.0 to $122.0 per share.
The stock has an average amount of shares sold short at 3.3%, and a short ratio of 2.1. The company's insiders own 0.78% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 98.9% of BioMarin Pharmaceutical's shares being owned by this investor type.
Institutions Invested in BioMarin Pharmaceutical
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Blackrock Inc. | 12% | 24,001,675 | $1,345,173,831 |
| 2025-06-30 | Vanguard Group Inc | 10% | 19,003,832 | $1,065,069,729 |
| 2025-06-30 | Primecap Management Company | 8% | 15,772,173 | $883,951,406 |
| 2025-06-30 | Dodge & Cox Inc | 8% | 15,108,310 | $846,745,206 |
| 2025-06-30 | Viking Global Investors, L.P. | 6% | 12,288,611 | $688,715,180 |
| 2025-06-30 | State Street Corporation | 5% | 8,847,751 | $495,872,188 |
| 2025-06-30 | AQR Capital Management, LLC | 3% | 5,580,573 | $312,763,203 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 3,474,438 | $194,724,871 |
| 2025-06-30 | Millennium Management Llc | 1% | 2,834,355 | $158,851,420 |
| 2025-06-30 | Morgan Stanley | 1% | 2,428,689 | $136,115,870 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on BioMarin Pharmaceutical.
